You are here

  • Home
  • Online First
  • Side effects of drug treatments for gastro-oesophageal reflux disease: current controversies

Article Text

Article menu

other Versions

Download PDFPDF
Oesophagus and stomach
Review
Side effects of drug treatments for gastro-oesophageal reflux disease: current controversies
  1. Anjan Dhar1,
  2. Frances Maw2,
  3. Helen Jane Dallal1,
  4. Stephen Attwood3
  1. 1Gastroenterology, County Durham & Darlington NHS Foundation Trust, Darlington, UK
  2. 2Pharmacy, County Durham and Darlington NHS Foundation Trust, Darlington, Darlington, UK
  3. 3Durham University, Durham, UK
  1. Correspondence to Professor Anjan Dhar, Gastroenterology, County Durham & Darlington NHS Foundation Trust, Darlington DL14 6AD, UK; adhar{at}nhs.net

Abstract

The two main drugs used in the treatment of gastro-oesophageal reflux disease are proton pump inhibitors and histamine-2 receptor antagonists and both these agents have been implicated in a number of adverse effects, leading to considerable controversies related to their long-term use. This paper is aimed at a critical review of the published literature and the clinical significance of these reported side effects, most of which are associations rather than causal.

  • acid-related diseases
  • adverse drug reactions
  • gastroesophageal reflux disease

https://doi.org/10.1136/flgastro-2019-101386

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Twitter @anjan_dhar6

    • Contributors AD, HJD and FM all contributed to the writing of the manuscript. AD revised the manuscript and is the senior author. SA provided a critique and contributed suggestions for improvement. AD is responsible for the overall content and is guarantor for the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Commissioned; externally peer reviewed.

    Linked Articles

    • UpFront
      Highlights from this issue
      R Mark Beattie
      Frontline Gastroenterology 2021; 13 1-2 Published Online First: 07 Dec 2021. doi: 10.1136/flgastro-2021-102066